PDCD1 and cancer: The response of immunotherapies, even targeting specific immune response molecules such as in the case of anti‐PD‐1/PD‐L1 ICB, is determined by multiple factors, including cancer cell immunogenicity, TME and the strength of local/systematic immune activity 80, 81, 82, 83, 84, 85.